{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:43:31Z","timestamp":1789137811478,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Eptinezumab\u2019s impact on self-reported work productivity in adults with migraine and 2\u20124 prior preventive migraine treatment failures is not fully understood.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methodology<\/jats:title>\n                <jats:p>Electronic diaries captured monthly migraine days (MMDs) reported by patients enrolled in the randomized, double-blind, placebo-controlled DELIVER trial (NCT04418765). The migraine-specific Work Productivity and Activity Impairment questionnaire, administered at baseline and each monthly visit, was a secondary outcome of DELIVER and used to model changes from baseline in self-reported monthly hours of absenteeism (decreased work attendance) and presenteeism (reduced work efficiency while at work with a migraine) in Canada, as the base case. Path analysis illustrated eptinezumab\u2019s impact on work productivity beyond MMDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>As MMDs increased, monthly hours of absenteeism increased linearly while those of presenteeism increased quadratically. Best-fit models were improved after including an eptinezumab treatment effect, showing benefit over placebo after controlling for MMD frequency. Compared to placebo, patients treated with eptinezumab (pooled) had a modeled reduction from baseline of 7.2\u00a0h\/month (absenteeism) (95% CI: \u22129.9, \u22124.5; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and 21.4\u00a0h\/month (presenteeism) (95% CI: \u221226.3, \u221216.5; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) over weeks 1\u201224. Beyond MMD reductions, improvements in patient-identified most bothersome symptom (PI-MBS) and reductions in percent of severe migraine attacks contributed to eptinezumab\u2019s effect.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Eptinezumab decreased absenteeism and presenteeism based on patient reports, with data highlighting the importance of considering the PI-MBS. The greater change from baseline than placebo in self-reported absenteeism and presenteeism was only partly explained by changes in MMDs, presenting a potential opportunity to decrease the cost of migraine in the workplace.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/\">ClinicalTrials.gov<\/jats:ext-link> (Identifier: NCT04418765); EudraCT (Identifier: 2019-004497-25)<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-024-00813-w","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:22:04Z","timestamp":1734531724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial"],"prefix":"10.1186","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-3755","authenticated-orcid":false,"given":"Piero","family":"Barbanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne F.","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Rae-Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane A.","family":"Regnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"1","key":"813_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"LJ Stovner","year":"2022","unstructured":"Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 23(1):34. https:\/\/doi.org\/10.1186\/s10194-022-01402-2","journal-title":"J Headache Pain"},{"issue":"5","key":"813_CR2","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84(5):422\u2013435. https:\/\/doi.org\/10.1016\/S0025-6196(11)60561-2","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"813_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-020-01144-z","volume":"21","author":"LP Wong","year":"2020","unstructured":"Wong LP, Alias H, Bhoo-Pathy N, Chung I, Chong YC, Kalra S, Shah Z (2020) Impact of migraine on workplace productivity and monetary loss: a study of employees in banking sector in Malaysia. J Headache Pain 21(1):68. https:\/\/doi.org\/10.1186\/s10194-020-01144-z","journal-title":"J Headache Pain"},{"issue":"14","key":"813_CR4","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1177\/0333102420944842","volume":"40","author":"AH Seddik","year":"2020","unstructured":"Seddik AH, Branner JC, Ostwald DA, Schramm SH, Bierbaum M, Katsarava Z (2020) The socioeconomic burden of migraine: an evaluation of productivity losses due to migraine headaches based on a population study in Germany. Cephalalgia 40(14):1551\u20131560. https:\/\/doi.org\/10.1177\/0333102420944842","journal-title":"Cephalalgia"},{"issue":"2","key":"813_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/head.12755","volume":"56","author":"A Messali","year":"2016","unstructured":"Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF, Stokes M, Lipton RB (2016) Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache 56(2):306\u2013322. https:\/\/doi.org\/10.1111\/head.12755","journal-title":"Headache"},{"issue":"5","key":"813_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.5271\/sjweh.3583","volume":"42","author":"W Zhang","year":"2016","unstructured":"Zhang W, McLeod C, Koehoorn M (2016) The relationship between chronic conditions and absenteeism and associated costs in Canada. Scand J Work Environ Health 42(5):413\u2013422. https:\/\/doi.org\/10.5271\/sjweh.3583","journal-title":"Scand J Work Environ Health"},{"issue":"5","key":"813_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-012-0460-7","volume":"13","author":"LM Bloudek","year":"2012","unstructured":"Bloudek LM, Stokes M, Buse DC, Wilcox TK, Lipton RB, Goadsby PJ, Varon SF, Blumenfeld AM, Katsarava Z, Pascual J, Lanteri-Minet M, Cortelli P, Martelletti P (2012) Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). J Headache Pain 13(5):361\u2013378. https:\/\/doi.org\/10.1007\/s10194-012-0460-7","journal-title":"J Headache Pain"},{"issue":"5","key":"813_CR8","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ, Steiner TJ, Barre J, Katsarava Z, Lainez JM, Lampl C, Lanteri-Minet M, Rastenyte D, Ruiz de la Torre E, Tassorelli C, Andree C (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19(5):703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"813_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-022-02774-3","volume":"22","author":"A Blumenfeld","year":"2022","unstructured":"Blumenfeld A, Ettrup A, Hirman J, Ebert B, Cady R (2022) Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab. BMC Neurol 22(1):251. https:\/\/doi.org\/10.1186\/s12883-022-02774-3","journal-title":"BMC Neurol"},{"issue":"9","key":"813_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/head.14196","volume":"61","author":"ELH Spierings","year":"2021","unstructured":"Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC (2021) Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study. Headache 61(9):1376\u20131386. https:\/\/doi.org\/10.1111\/head.14196","journal-title":"Headache"},{"issue":"1","key":"813_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s10194-022-01521-w","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Goadsby PJ, Lambru G, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B (2022) Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study. J Headache Pain 23(1):153. https:\/\/doi.org\/10.1186\/s10194-022-01521-w","journal-title":"J Headache Pain"},{"issue":"1","key":"813_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s10194-024-01752-z","volume":"25","author":"L Jonsson","year":"2024","unstructured":"Jonsson L, Awad SF, Regnier SA, Talon B, Kymes S, Lee XY, Goadsby PJ (2024) Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab. J Headache Pain 25(1):45. https:\/\/doi.org\/10.1186\/s10194-024-01752-z","journal-title":"J Headache Pain"},{"issue":"7","key":"813_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1080\/14737167.2023.2219898","volume":"23","author":"L Jonsson","year":"2023","unstructured":"Jonsson L, Regnier SA, Kymes S, Awad SF, Talon B, Lee XY, Goadsby PJ (2023) Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial. Expert Rev Pharmacoecon Outcomes Res 23(7):797\u2013803. https:\/\/doi.org\/10.1080\/14737167.2023.2219898","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"813_CR14","doi-asserted-by":"publisher","unstructured":"CADTH reimbursement recommendation eptinezumab (Vyepti) (2023) Can J Health Technol 3(1):1\u201324. https:\/\/doi.org\/10.51731\/cjht.2023.537","DOI":"10.51731\/cjht.2023.537"},{"key":"813_CR15","doi-asserted-by":"publisher","unstructured":"Barbanti P, Awad SF, Regnier SA, Lee X, Goadsby PJ (2023) Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial (P13-12.012). Neurology 100(17_supplement_2). https:\/\/doi.org\/10.1212\/WNL.0000000000202965","DOI":"10.1212\/WNL.0000000000202965"},{"issue":"7","key":"813_CR16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, Ettrup A, Christoffersen CL, Josiassen MK, Phul R, Sperling B (2022) Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5","journal-title":"Lancet Neurol"},{"issue":"5","key":"813_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4(5):353\u2013365. https:\/\/doi.org\/10.2165\/00019053-199304050-00006","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"813_CR18","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/head.14120","volume":"61","author":"RB Lipton","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R (2021) Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache 61(5):766\u2013776. https:\/\/doi.org\/10.1111\/head.14120","journal-title":"Headache"},{"issue":"6","key":"813_CR19","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/head.14295","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Goadsby PJ, Dodick DW, McGinley JS, Houts CR, Wirth RJ, Kymes S, Ettrup A, Osterberg O, Cady R, Ashina M, Buse DC (2022) Evaluating the clinical utility of the patient-identified most bothersome symptom measure from PROMISE-2 for research in migraine prevention. Headache 62(6):690\u2013699. https:\/\/doi.org\/10.1111\/head.14295","journal-title":"Headache"},{"key":"813_CR20","doi-asserted-by":"publisher","unstructured":"Statistics Canada (2023) Average usual and actual hours worked in a reference week by type of work (full- and part-time), annual [Table: 14-10-0043-01]. https:\/\/doi.org\/10.25318\/1410004301-eng. Accessed 9 Mar 2023","DOI":"10.25318\/1410004301-eng"},{"key":"813_CR21","unstructured":"U.S. Bureau of Labor Statistics. Household data, Annual averages, Table 19. Persons at work in agriculture and nonagricultural industries by hours of work. https:\/\/www.bls.gov\/cps\/cps_aa2021.htm. Last modified: Jan. 19, 2023. Accessed 23 Mar 2023"},{"key":"813_CR22","unstructured":"Office for National Statistics (2023) Average actual weekly hours of work for full-time workers (seasonally adjusted). https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/timeseries\/ybuy\/lms. Accessed 23 Mar 2023"},{"key":"813_CR23","unstructured":"Institut f\u00fcr Arbeitsmarkt- und Berufsforschung (IAB) (2023) Average working hours and their components. https:\/\/iab.de\/en\/daten\/iab-working-time-measurement-concept\/. Accessed 23 Mar 2023"},{"key":"813_CR24","doi-asserted-by":"publisher","unstructured":"Statistics Canada (2023) Employee wages by industry, 25 to 54 years, annual [Table: 14-10-0064-01]. https:\/\/doi.org\/10.25318\/1410006401-eng. Accessed 9 Mar 2023","DOI":"10.25318\/1410006401-eng"},{"key":"813_CR25","unstructured":"U.S. Bureau of Labor Statistics May 2021 National Occupational Employment and Wage Estimates [Table #00-0000]. https:\/\/www.bls.gov\/oes\/current\/oes_nat.htm. Last modified: Mar. 31, 2022. Accessed 23 Mar 2023"},{"key":"813_CR26","unstructured":"Office for National Statistics (2023) EARN01: average weekly earnings. https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/datasets\/averageweeklyearningsearn01. 23 Accessed Mar 2023"},{"key":"813_CR27","unstructured":"Statistisches Bundesamt (Destatis; German Federal Statistical Office) (2023) https:\/\/www.destatis.de\/EN\/Themes\/Labour\/Earnings\/Earnings-Earnings-Differences\/current-economic-activity.html. Accessed 23 Mar 2023."},{"issue":"1","key":"813_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s10194-019-0993-0","volume":"20","author":"M Leonardi","year":"2019","unstructured":"Leonardi M, Raggi A (2019) A narrative review on the burden of migraine: when the burden is the impact on people\u2019s life. J Headache Pain 20(1):41. https:\/\/doi.org\/10.1186\/s10194-019-0993-0","journal-title":"J Headache Pain"},{"key":"813_CR29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2147\/CEOR.S304158","volume":"13","author":"J Ford","year":"2021","unstructured":"Ford J, Nichols RM, Ye W, Tockhorn-Heidenreich A, Cotton S, Jackson J (2021) Patient-reported outcomes for migraine in the US and Europe: burden associated with multiple preventive treatment failures. Clinicoecon Outcomes Res 13:647\u2013660. https:\/\/doi.org\/10.2147\/CEOR.S304158","journal-title":"Clinicoecon Outcomes Res"},{"issue":"2","key":"813_CR30","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40122-019-0133-1","volume":"8","author":"MJ Doane","year":"2019","unstructured":"Doane MJ, Gupta S, Vo P, Laflamme AK, Fang J (2019) Associations between headache-free days and patient-reported outcomes among migraine patients: a cross-sectional analysis of survey data in Europe. Pain Ther 8(2):203\u2013216. https:\/\/doi.org\/10.1007\/s40122-019-0133-1","journal-title":"Pain Ther"},{"issue":"1","key":"813_CR31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s10194-023-01688-w","volume":"24","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Gendolla A, Sperling B, Ettrup A, Josiassen MK, Starling AJ (2023) Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial. J Headache Pain 24(1):155. https:\/\/doi.org\/10.1186\/s10194-023-01688-w","journal-title":"J Headache Pain"},{"issue":"3","key":"813_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler B, Biondi DM, Hirman J, Pederson S, Allan B, Smith J (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254. https:\/\/doi.org\/10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"issue":"13","key":"813_CR33","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000009169","volume":"94","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, Pederson S, Allan B, Cady R (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365\u2013e1377. https:\/\/doi.org\/10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"issue":"10","key":"813_CR34","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/head.14007","volume":"60","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S (2020) Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache 60(10):2220\u20132231. https:\/\/doi.org\/10.1111\/head.14007","journal-title":"Headache"},{"issue":"10","key":"813_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.18553\/jmcp.2020.20103","volume":"26","author":"RB Lipton","year":"2020","unstructured":"Lipton RB, Lee L, Saikali NP, Bell J, Cohen JM (2020) Effect of headache-free days on disability, productivity, quality of life, and costs among individuals with migraine. J Manag Care Spec Pharm 26(10):1344\u20131352. https:\/\/doi.org\/10.18553\/jmcp.2020.20103","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"813_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s10194-018-0907-6","volume":"19","author":"P Vo","year":"2018","unstructured":"Vo P, Fang J, Bilitou A, Laflamme AK, Gupta S (2018) Patients\u2019 perspective on the burden of migraine in Europe: a cross-sectional analysis of survey data in France, Germany, Italy, Spain, and the United Kingdom. J Headache Pain 19(1):82. https:\/\/doi.org\/10.1186\/s10194-018-0907-6","journal-title":"J Headache Pain"},{"issue":"6","key":"813_CR37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/0333102420977852","volume":"41","author":"O Begasse de Dhaem","year":"2021","unstructured":"Begasse de Dhaem O, Gharedaghi MH, Bain P, Hettie G, Loder E, Burch R (2021) Identification of work accommodations and interventions associated with work productivity in adults with migraine: a scoping review. Cephalalgia 41(6):760\u2013773. https:\/\/doi.org\/10.1177\/0333102420977852","journal-title":"Cephalalgia"},{"issue":"12","key":"813_CR38","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.37765\/ajmc.2020.88547","volume":"26","author":"A Yucel","year":"2020","unstructured":"Yucel A, Thach A, Kumar S, Loden C, Bensink M, Goldfarb N (2020) Estimating the economic burden of migraine on US employers. Am J Manag Care 26(12):e403\u2013e408. https:\/\/doi.org\/10.37765\/ajmc.2020.88547","journal-title":"Am J Manag Care"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-024-00813-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-024-00813-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T15:18:06Z","timestamp":1734535086000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-024-00813-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1186\/s41687-024-00813-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"8 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The DELIVER study was conducted in accordance with standards of Good Clinical Practice as defined by the International Conference on Harmonisation and all applicable federal and local regulations. The local review board or a central institutional review board\/ethics committee approved all study documentation at each of the 96 study sites. All patients provided written informed consent prior to study participation. DELIVER is registered on ClinicalTrials.gov (NCT04418765) and EudraCT (2019-004497-25).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PB reports, over the last 36 months, travel grants, honoraria for advisory boards, speaker panels or clinical investigation studies from Alder, Allergan, Angelini, Assosalute, Bayer, electroCore, Eli Lilly, GSK, Lundbeck, Lusofarmaco, 1MED, MSD, New Penta, Noema Pharma, Novartis, Stx-Med, Teva, Visufarma, and Zambon. SFA, SAR, and XYL are employees of H. Lundbeck A\/S, Copenhagen, Denmark. HRE was an employee of Clinigma, Copenhagen, Denmark, at the time the exit interviews were conducted. PJG reports, over the last 36 months, a grant from Celgene, and personal fees from Aeon Biopharma, Allergan\/AbbVie, CoolTech LLC, Dr. Reddy\u2019s, Eli Lilly, Epalex, Impel Neuropharma, Lundbeck, Novartis, Pfizer, Praxis, Sanofi, Satsuma, Teva, and Tremeau. He also reports personal fees for advice through Gerson Lehrman Group, Guidepoint, SAI Med Partners, and Vector Metric; fees for educational materials from CME Outfitters and WebMD; publishing royalties or fees from Massachusetts Medical Society, Oxford University Press, UpToDate, and Wolters Kluwer; fees for medicolegal advice in headache; and a patent for magnetic stimulation for headache (No. WO2016090333 A1) assigned to eNeura without fee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}